TIEFENBACHER and active pharmaceutical ingredients
A corporation growing through challenges
It is the long standing and profound knowledge of the continuously changing API market and its significance in healthcare, as well as anticipation and flexibility when dealing with radical changes in the industry that have allowed AET to grow over the last 50 years.
Through relationships with leading principals, suppliers and clients based on successful and trusting collaboration, TIEFENBACHER has the experience and ability to exceed the needs of the pharmaceutical and API industries.
TIEFENBACHER as API Sourcer
The power of networking
Transparency in the relationship between the manufacturer, the commissioner and TIEFENBACHER is of paramount importance in delivering value to TIEFENBACHERs clients, and promotes trusting and open collaborations that are best able to innovate and be efficient in dealing with complex and challenging situations.
In the perfectly established network of pharmaceutical disciplines TIEFENBACHERs core competence is still the API business. By focusing on API in every aspect of the business, based on the experience of more than 50 years and close and continuous relationships with API manufacturers, TIEFENBACHER is one of the most successful API producers and marketers worldwide.
TIEFENBACHER and active substances 2019
The combination of networking, continuity and enduring quality.
APIs
TIEFENBACHER makes no claims as to the patent status of the products in this list. Should intellectual property exist, TIEFENBACHER will be unable to offer or sell the affected API.
Last update: October 2019
Intermediates
TIEFENBACHER makes no claims as to the patent status of the products in this list. Should intellectual property exist, TIEFENBACHER will be unable to offer or sell the affected API.
Last update: October 2019
Excipients
TIEFENBACHER makes no claims as to the patent status of the products in this list. Should intellectual property exist, TIEFENBACHER will be unable to offer or sell the affected API.
Last update: October 2019